

mRNA Integrity by Agilent 5300 Fragment Analyzer

Shauna Salem

Analytical Research and Development

Pfizer, Andover, MA

17-Sep-2024

Outline

mRNA Vaccines

Agilent 5300 Fragment Analyzer Overview

Case Studies

Summary and Conclusions







mRNA Vaccines

mRNA Vaccines and RNA Integrity


- Pfizer has several mRNA vaccine products with a wide variety of sizes and disease targets
- RNA integrity is a critical quality attribute
 - It directly impacts efficacy, product period of use, storage conditions, and shipping tolerances
- Pfizer's release purity method is capillary gel electrophoresis (CGE) using the Agilent 5300 Fragment Analyzer



Manufacture and Testing of mRNA



mRNA Drug Substance Quality Control Strategy



5' – Cap attributes by LC/MS & LC/UV

Poly(A) Tail attributes by PCR and LC/UV-MS


Platform QC Assays

- Compendial methods
- **Purity by Capillary Gel Electrophoresis**
- Concentration by UV spectroscopy
- Identity, Impurities by PCR-based methods
- Purity by Immunoblot



Characterization Assays

- NextGen Sequencing (NGS)
- Nucleoside/tide and Oligonucleotide mapping LC-MS/MS
- Higher Order Structure by Circular Dichroism (CD)
- Protein Expression Western Analysis

mRNA Drug Product Quality Control Strategy



Four Functional & Structural Lipids



Lipid Nanoparticle

Lipid ID and Content by LC-CAD
LNP Size and Polydispersity by DLS
In Vitro Expression by Cell-based FACS

Platform QC Assays

- Compendial & Safety methods
- Purity by Capillary Gel Electrophoresis
- Content, RNA Encapsulation by Fluorescence Assay
- Identity by PCR-based method

Characterization Assays

- Lipid ID and content by LC-MS
- LNP surface properties by high-field NMR
- LNP surface charge by Zeta potential
- Orthogonal size measurements



Agilent 5300 Fragment Analyzer Overview

Fragment Analyzer Principles


- Multiplexed capillary electrophoresis system
 - 12, 48, or 96 capillary array
- Multiplexed - All samples are run simultaneously
- Analyze RNA
 - Kits are available to purchase
- Assay output
 - Relative purity of intact RNA vs. fragmented RNA
 - Approximate size (nucleotides)
- Separation is achieved by applying an electric field through the capillary array filled with gel, separating based on size
 - Smaller species migrating before larger species
- Detection of the separated RNA is achieved by fluorescence
- Run time is ~1.5 hours, FAST!



Sample Preparation

- Highly recommend preparing samples in a PCR hood or BSC with RNase free handling practices [Minimize lab induced fragmentation]
- Drug substance
 - Dilute to nominal concentration
- Drug product
 - Dilute to nominal concentration
 - Disrupt with detergent and alcohol solution
- In a 96 well plate, combine diluent marker (Agilent kit component that contains formamide to aid in denaturation) and sample
- Perform heat incubation for denaturation
- Sample preparation time is ~1.5 hours (varies based on # of samples)
- See Agilent kit literature for more details!


Drug Product Disruption



Time Corrected Area (TCA) – A Brief Side Note

- CGE separation is based on size
- Smaller species migrate faster than larger species (migration velocity)
- Smaller species spend less time in front of the detector compared to larger species
- TCA accounts for the difference in migration velocity
- $TCA = \frac{Area}{Migration\ Time}$

Integration by Smear Analysis




- The Agilent software ProSize is used to integrate results by smear analysis
- Smear ranges are set for a peak or region (i.e. intact RNA peak)
- % Species are calculated by total TCA above baseline, **instead of only integrated peaks**
- Area above baseline is auto sliced by the software (blue lines added for visualization, actual quantity of slices is near infinite)
- For each slice TCA is calculated in the background from smear algorithms using the time stamp of the slice, instead of using apex for entire region
- This is an efficient and appropriate way of calculating TCA for this type of data



Pre-Validation Case Study; Precision and Linearity

System Precision – mRNA DS

A measure of the degree of repeatability of the instrument for multiple aliquots from a single sample




| Sample | % RNA Integrity |
|---------------------------|-----------------|
| System Precision #1 | 89.3 |
| System Precision #2 | 89.9 |
| System Precision #3 | 89.2 |
| System Precision #4 | 88.7 |
| System Precision #5 | 89.1 |
| System Precision #6 | 89.5 |
| Average | 89.3 |
| Standard Deviation | 0.398 |
| % RSD | 0.4% |

- 6 analyses from a single preparation
- Acceptable degree of precision
 - **Instrument variability is low within run**

Method Precision – mRNA DS

A measure of the degree of repeatability of the method for single aliquots from multiple sample preparations



| Sample | % RNA Integrity |
|---------------------------|-----------------|
| Method Precision #1 | 89.3 |
| Method Precision #2 | 89.5 |
| Method Precision #3 | 89.2 |
| Method Precision #4 | 88.6 |
| Method Precision #5 | 90.4 |
| Method Precision #6 | 90.5 |
| Average | 89.6 |
| Standard Deviation | 0.726 |
| % RSD | 0.8% |

- 6 separate preparations
- Acceptable degree of precision
 - **Preparation variability is low**

Intermediate Precision – mRNA DS



A measure of a variety of inter/intra-laboratory test conditions, multiple analysts/instruments/(may expand to labs)

| Lab | Instance | Analyst | Instrument | % RNA Integrity |
|---------------------------|----------|---------|------------|-----------------|
| 1 | 1 | 1 | 1 | 89.3 |
| | 2 | 1 | 2 | 90.0 |
| | 3 | 1 | 3 | 89.1 |
| | 4 | 2 | 2 | 91.2 |
| | 5 | 2 | 3 | 89.3 |
| | 6 | 2 | 1 | 89.7 |
| Average | | | | 89.8 |
| Standard Deviation | | | | 0.774 |
| % RSD | | | | 0.9% |

- More realistic view – evaluate variability impact of analysts/instruments/labs
- Acceptable degree of precision
 - **Analyst and instrument variability is low**

Linearity – mRNA DS

To determine the ability of the analytical method to elicit results that are directly proportional to the concentration of analyte in the sample over a given concentration range




- Assay is linear from 20 to 150% of nominal load
- **Large linear range**



Forced Degradation Stability Case Study


Forced Degradation Stability Study - mRNA DS


The assay is stability indicating



Forced Degradation Stability Study - mRNA DP

The assay is stability indicating





Standard Sensitivity Kit vs. High Sensitivity Kit Case Study

Standard Sensitivity (SS) Kit vs. High Sensitivity (HS) Kit

- SS and HS kits have similar separation and detection parameters
- The prepared sample concentration in the SS kit is higher and the injection duration is shorter (relative to the HS kit)
- The HS kit optimizes the intensity of the lower RNA marker peak and the RNA ladder to allow for low concentration samples to be injected for significantly longer injection durations
- Both kits achieve the same relative on-capillary load
- An established RFU range for main peak apex enables control of capillary load for both kit methods

Standard Sensitivity Kit


- Part # DNF-471-1000
- Higher concentration samples
- Low injection duration

High Sensitivity Kit

- Part # DNF-472-1000
- Low concentration samples
- High injection duration

Standard Sensitivity (SS) Kit vs. High Sensitivity (HS) Kit - mRNA DP

SS and HS kits provide comparable results



Summary and Conclusions

- RNA integrity is a critical quality attribute which can be measured using the Agilent 5300 Fragment Analyzer
- Agilent 5300 Fragment Analyzer Pros:
 - High throughput
 - Fast sample preparation
 - Fast run time
 - Two kits available to purchase covering a wide range of sample concentrations
 - Robust method in routine use at Pfizer



Acknowledgments

Pfizer

- David Ripley
- Gaofei He
- Benjamin Vincent
- Mary Chum
- David Cirelli
- Tanya Shang
- Thomas Lerch
- Analytical Research & Development (Andover, MA and Chesterfield, MO)

Agilent

- Steve Siembieda
- Whitney Pike
- Kyle Luttgarm
- Matthew Freeley



Thank You and Questions

